These findings carried important clinical implications: The ROS/p-p38/NOXA axis emerged as a druggable target for TP53mutant NSCLC, particularly relevant given the high prevalence of TP53 mutations in NSCLC [4]. The gene discussed is PMAIP1; the disease is non-small cell lung carcinoma.